Get the Stockscreener App
1.69
1.17%
-0.02
After Hours:
1.70
0.01
+0.59%
Ikena Oncology Inc stock is traded at $1.69, with a volume of 97,050.
It is down -1.17% in the last 24 hours and down -1.74% over the past month.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
See More
Previous Close:
$1.71
Open:
$1.75
24h Volume:
97,050
Relative Volume:
1.81
Market Cap:
$82.28M
Revenue:
$9.16M
Net Income/Loss:
$-68.17M
P/E Ratio:
-0.9941
EPS:
-1.7
Net Cash Flow:
$-80.16M
1W Performance:
-0.59%
1M Performance:
-1.74%
6M Performance:
+27.07%
1Y Performance:
+4.97%
1-Day Range:
$1.69
$1.75
1-Week Range:
$1.67
$1.771
52-Week Range:
$1.22
$2.32
Ikena Oncology Inc Stock (IKNA) Company Profile
Name
Ikena Oncology Inc
Sector
Industry
Phone
857-343-8292
Address
50 NORTHERN AVE., BOSTON
Compare IKNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.69 | 82.28M | 9.16M | -68.17M | -80.16M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| May-04-23 | Resumed | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Jefferies | Buy |
| Apr-20-21 | Initiated | William Blair | Outperform |
View All
Ikena Oncology Inc Stock (IKNA) Latest News
Ikena Oncology FY2024 EPS Estimate Boosted by HC Wainwright - Defense World
Ikena Oncology FY2024 EPS Forecast Lifted by HC Wainwright - MarketBeat
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Earns “Buy” Rating from HC Wainwright - Defense World
Ikena Oncology (NASDAQ:IKNA) Given "Buy" Rating at HC Wainwright - MarketBeat
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) - Yahoo Finance
Wedbush Reaffirms “Neutral” Rating for Ikena Oncology (NASDAQ:IKNA) - Defense World
Ikena Oncology Reports Strategic Realignment and Financial Performance - TipRanks
Ikena Oncology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Ikena Oncology Reports 41% Lower Net Loss, Strong $138M Cash Position in Q3 | IKNA Stock News - StockTitan
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update - MarketBeat
Renaissance Technologies LLC Sells 300,200 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Point72 Asia Singapore Pte. Ltd. Invests $75,000 in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology’s Gamble: Slashing Workforce by Half Could Derail Strategic Plans - TipRanks
Point72 Asia Singapore Pte. Ltd. Purchases Shares of 45,520 Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Acadian Asset Management LLC Has $536,000 Stake in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Analyzing Ikena Oncology (NASDAQ:IKNA) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Large Drop in Short Interest - MarketBeat
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Down 10.7% in July - Defense World
Q3 2024 EPS Estimates for Ikena Oncology, Inc. (NASDAQ:IKNA) Lifted by HC Wainwright - MarketBeat
Ikena Oncology, Inc. (NASDAQ:IKNA) Expected to Post Q3 2024 Earnings of ($0.26) Per Share - Defense World
HC Wainwright Reaffirms "Buy" Rating for Ikena Oncology (NASDAQ:IKNA) - MarketBeat
Ikena Oncology (NASDAQ:IKNA) Receives Buy Rating from HC Wainwright - Defense World
Ikena Oncology (NASDAQ:IKNA) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - Defense World
Ikena Oncology Reports Second Quarter 2024 Financial Results - GlobeNewswire
Jacobs Levy Equity Management Inc. Increases Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Jacobs Levy Equity Management Inc. Boosts Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - MarketBeat
Acadian Asset Management LLC Raises Position in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Decline in Short Interest - MarketBeat
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting - Barchart
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Drop in Short Interest - Defense World
Ikena Oncology expands role of CFO Jotin Marango to COO - Investing.com
Ikena Oncology Promotes Jotin Marango to Chief Operating Officer - TipRanks
New Strong Buy Stocks for July 12th - Yahoo Finance
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround - MSN
Take off with Ikena Oncology Inc (IKNA): Get ready for trading – Sete News - SETE News
Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Decreases By 9.0% - MarketBeat
Fierce Biotech Layoff Tracker 2024: Takeda axes another 220 jobs; Ovid undergoes 43% reduction - Fierce Biotech
Ikena Oncology - The Pharma Letter
HC Wainwright & Co. Reiterates Ikena Oncology (IKNA) Buy Recommendation - MSN
Why Ikena Oncology (IKNA) Might Surprise This Earnings Season - Yahoo News Malaysia
Head and Neck cancer Pipeline Forecast 2024: FDA Approvals, - openPR
Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update - Quantisnow
Ikena Oncology Announces $40 Million Underwritten Offering - Quantisnow
Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference - Quantisnow
Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022 - Quantisnow
Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer - Quantisnow
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference - Quantisnow
Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year ... - Yahoo Movies UK
Examining Ikena Oncology Inc (IKNA) stock is warranted – US Post News - US Post News
Ikena Oncology, Inc.'s (NASDAQ:IKNA) largest shareholders are private equity firms with 46% ownership, institutions ... - Yahoo Canada Sports
Ikena Oncology Inc Stock (IKNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):